Day One Biopharmaceuticals, Inc.
DAWN
$7.46
$0.497.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 187.64M | 161.92M | 131.16M | 101.95M | 8.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 187.64M | 161.92M | 131.16M | 101.95M | 8.19M |
| Cost of Revenue | 11.22M | 8.16M | 5.28M | 2.30M | 707.00K |
| Gross Profit | 176.42M | 153.76M | 125.88M | 99.66M | 7.49M |
| SG&A Expenses | 117.00M | 118.22M | 115.45M | 107.88M | 97.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 299.38M | 353.49M | 343.43M | 308.41M | 295.72M |
| Operating Income | -111.74M | -191.57M | -212.27M | -206.46M | -287.53M |
| Income Before Tax | -89.40M | -61.94M | -88.35M | -83.62M | -165.93M |
| Income Tax Expenses | 5.59M | 7.14M | 7.14M | 670.00K | 1.55M |
| Earnings from Continuing Operations | -95.00 | -69.08 | -95.50 | -84.29 | -167.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.00M | -69.08M | -95.50M | -84.29M | -167.48M |
| EBIT | -111.74M | -191.57M | -212.27M | -206.46M | -287.53M |
| EBITDA | -108.81M | -189.21M | -210.71M | -205.50M | -287.17M |
| EPS Basic | -0.90 | -0.66 | -1.03 | -1.02 | -1.94 |
| Normalized Basic EPS | -0.53 | -0.37 | -0.56 | -0.60 | -1.17 |
| EPS Diluted | -0.91 | -0.66 | -1.03 | -1.03 | -1.95 |
| Normalized Diluted EPS | -0.53 | -0.37 | -0.56 | -0.60 | -1.17 |
| Average Basic Shares Outstanding | 404.84M | 388.90M | 372.87M | 356.47M | 345.80M |
| Average Diluted Shares Outstanding | 405.16M | 389.21M | 373.18M | 356.78M | 345.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |